Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Storm, Andrew C.; Dayyeh, Barham K. Abu

doi:10.1016/j.gie.2019.02.025

Cited by 37 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we all know that all bariatric procedures have an important effect during the first 12 to 18 months. Initial report of EG showed similar efficiency and durability (8)(9)(10). Moreover, it should also be mentioned that EG present another important advantages.…”

Section: Discussionmentioning

confidence: 90%

Endoscopic Gastroplasty. Initial Experience

Manos¹,

Noe͏̈l²,

Bastid³

et al. 2019

chr

View full text Add to dashboard Cite

RezumatIntroducere: Procedurile bariatice endoscopice, în curs de dezvoltare, sunt mult mai puţin invazive ca opţiune de tratament pentru clasa I de obezitate. Scopul studiului nostru a fost de a evalua experienţa iniţială pe un an cu gastroplastia endoscopică (GE) din punct de vedere al rezultatelor ponderale, cât şi pentru evaluarea riscurilor acestei noi proceduri. Metode: Acesta este un studiu prospectiv într-un singur centru pe 17 pacienţi care au beneficiat de GE sub anestezie generală. Variabilele analizate au fost: modificarea greutăţii corporale şi complicaţiile procedurii. Pentru a analiza corelaţiile dintre IMC şi pentru a identifica factorii predictori pentru o mai bună pierdere în greutate după GE, pacienţii au fost divizaţi în 2 grupuri: grupa A (cu IMC < 35 şi fără antecedente bariatrice -10 pacienţi) şi grupa B (cu IMC > 35, sau cu antecedente de balon gastric sau chirurgie bariatrică -7 cazuri). Rezultate: Un total de 17 pacienţi au beneficiat de GE pentru obezitatea primară sau recidivă. Toţi pacienţii au fost de sex feminin, cu o vârstă medie de 38,7 ani. Media IMC a fost de 34,8 kg /m 2 (interval: 30,8 -44,1). Nu au existat complicaţii în timpul procedurii sau în perioada de după. Toţi pacienţii au fost externaţi în prima sau a doua zi după procedură, iar în viitor procedura va fi propusă în ambulatoriu. Patru pacienţi (23,5%) au prezentat durere postprocedurală moderată pe o perioadă medie de 7,75 zile (interval de 2-15 zile), iar alţi doi pacienţi au prezentat greaţă şi

show abstract

Section: Discussionmentioning

confidence: 90%

Endoscopic Gastroplasty. Initial Experience

Manos¹,

Noe͏̈l²,

Bastid³

et al. 2019

chr

View full text Add to dashboard Cite

show abstract

“…No patients required emergency intervention and there were no mortalities. A review by Storm and Abu Dayyeh 30 reported data on 1607 cases reported from large multicenter studies to provide evidence for the safety and efficacy of this procedure. They found %TWL across these studies at 6, 12, and 18 months or more to be 15.8, 17.1, and 17.3, respectively.…”

Section: Endoscopic Sleeve Gastroplastymentioning

confidence: 99%

Overview of bariatric and metabolic endoscopy interventions

Tawadros

Makar

Kahaleh

et al. 2020

Clin Med Insights Gastroenterol

View full text Add to dashboard Cite

The rise of endoscopic techniques allowing weight loss offers an attractive alternative to surgical interventions in Western countries where the obesity epidemic has risen dramatically. Endoscopists are well positioned to manage obesity given their broad-based medical knowledge, understanding of gastrointestinal physiology, and training in endoscopic technique. The field of bariatric and metabolic endoscopy has permitted the development of several efficacious and safe technologies. This review focuses on techniques and devices used for endoscopic management of obesity, as well as the fundamental justifications to offer those therapies to obese patients.

show abstract

“…The FDA has not specifically approved the OverStitch device for ESG indication. A meta-analysis of published series involving 1607 individuals demonstrated a pooled %TBWL of 17.1% and 17.3% at 12 and 18 or more months with a serious adverse event rate of 1.1% without any reported perforation or death [30]. One potential advantage of ESG as compared to sleeve gastrectomy is that it causes less de novo gastroesophageal reflux disease (1.9% vs. 14.5%), increasingly recognized as a source of morbidity after sleeve gastrectomy.…”

Section: Endoscopic Suturing and Plication Proceduresmentioning

confidence: 99%

Endoscopic Treatment for Obesity and Weight Management: State of the Art

Jaruvongvanich¹,

Storm²,

Dayyeh³

2020

Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy

View full text Add to dashboard Cite

Obesity is a rising pandemic associated with numerous comorbidities and increased mortality. Although effective and durable, bariatric surgery is performed in less than 1% of eligible candidates. It has been underutilized due to its invasiveness, costs, and risk profile. At the other end of the obesity treatment spectrum, lifestyle intervention frequently fails to achieve effective and durable weight loss. Endoscopic bariatric therapies have emerged to bridge this treatment

show abstract

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Cited by 37 publications

References 7 publications

Endoscopic Gastroplasty. Initial Experience

Endoscopic Gastroplasty. Initial Experience

Overview of bariatric and metabolic endoscopy interventions

Endoscopic Treatment for Obesity and Weight Management: State of the Art

Contact Info

Product

Resources

About